A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia CLL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03701282

Study #:
STUDY00143595

Start Date:
May 28, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03701282

View Complete Trial Details & Eligibility at ClinicalTrials.gov